Information services provider Thomson Reuters, US, has announced the launch of the Newport Biologics Module, claimed to be the most essential source of competitive intelligence for the rapidly growing market in biologic and biosimilar drugs.
The development of biological drugs has seen a dramatic increase during the past five years with nearly 6,000 clinical trials with a biological intervention being reported since 2005, according to Thomson Reuters. With this increase have come new government regulations promoting competition in the sector.
The Newport Biologics Module claims to be a vital addition to the Thomson Reuters Newport Premium solution and will allow generic drug companies, biotech firms or manufacturers of active pharmaceutical ingredients (API), to assess their own opportunities to enter the biosimilars market or to spot potential competitive activity.
The module provides unique manufacturing process data covering biologic drugs, including recombinant proteins, antibodies, factors, and vaccines. Companies considering pursuing biosimilar opportunities can analyse multiple potential bio-manufacturing processes for each drug, genetic sequences, process steps, starting materials, and equipment required, as well as review related patents and literature.
Thomson Reuters Newport products is built on more than a decade's experience of supplying solutions to meet the critical business challenges in the highly competitive and global generic and API markets. These products are now used by more than 250 of the world's leading generic companies and API manufacturers operating in 60 countries around the world.
Thomson Reuters Newport Premium integrates intelligence on more than 40,000 launched products with more than 300,000 brand names containing over 10,000 different active ingredients and over 20,000 corporate groups involved with manufacturing and marketing dose products of both small molecule and biologic active ingredients.
Search for more Reference Tools
To access our daily STM news feed through your iPhone, iPad, or other smartphones, please visit www.myscoope.com for a mobile friendly reading experience.
